Jackie S. Fairweather, RN | Authors

Phase I Study of Irinotecan and Concurrent Radiation Therapy for Upper GI Tumors

December 03, 2000

Irinotecan (Camptosar) is an active chemotherapeutic agent for lung, gastric, esophageal, and colorectal cancers and a potent radiosensitizer. This phase I study was designed to assess the maximum tolerated dose of weekly

Irinotecan and Cisplatin in Advanced Gastric or Gastroesophageal Junction Carcinoma

December 01, 2000

Chemotherapy for advanced gastric and gastroesophageal junction carcinomas remains suboptimal. Both irinotecan (Camptosar) and cisplatin (Platinol) are active against this group of malignancies. This article focuses